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Hepatocyte growth factor (HGF) and its receptor Met are
responsible for a wide variety of cellular responses, both
physiologically during embryo development and tissue
homeostasis, and pathologically, particularly during
tumor growth and dissemination. In cancer, Met can act
as an oncogene on tumor cells, as well as a pro-angiogenic
factor activating endothelial cells and inducing new vessel
formation. Molecules interfering with Met activity could
be valuable therapeutic agents. Here we have investigated
the antiangiogenic properties of a synthetic peptide
mimicking the docking site of the Met carboxyl-terminal
tail, which was delivered into the cells by fusion with the
internalization sequences from Antennapedia or HIV-Tat.
We showed that these peptides inhibit ligand-dependent
endothelial cell proliferation, motility, invasiveness and
morphogenesis in vitro to an even greater extent and with
much less toxicity than the Met inhibitor PHA-665752,
which correlated with interference of HGF-dependent
downstream signaling. In vivo, the peptides inhibited
HGF-induced angiogenesis in the matrigel sponge assay
and impaired xenograft tumor growth and vascularization in
Kaposi’s sarcoma. These data show that interference with
the Met receptor intracellular sequence impairs HGF-
induced angiogenesis, suggesting the use of antidocking site
compounds as a therapeutic strategy to counteract angio-
genesis in cancer as well as in other diseases.
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Introduction
Angiogenesis contributes to cancer initiation and
progression and to several other pathologies, such as
chronic inﬂammation, retinopathies and arthritis
(Carmeliet and Jain, 2000). The formation of a
tumor-associated vasculature, a process referred to as
tumor angiogenesis, is essential for cancer progression
and metastasis and has become a clinical target for
anticancer therapy. Current clinical approaches all
focus on blocking a common hypoxia-associated
angiogenic factor, vascular endothelial growth factor
(VEGF), by either sequestering the factor itself or
inhibiting its receptors. Although effective in slowing
tumor progression, tumor escape through a variety
of mechanisms, including up-regulation of other
angiogenic growth factors, is frequently encountered
(Loges et al., 2009).
The receptor for the human hepatocyte growth factor
(HGF), encoded by MET oncogene, has an important
physiological role in a complex morphogenetic program
known as invasive growth, occurring both during
embryonic development and during adult life. In
pathological conditions, unregulated HGF-Met signal-
ing can trigger tumor growth and metastasis (Boccaccio
and Comoglio, 2006). Met is predominantly expressed
by epithelial cells (Di Renzo et al., 1991; Prat et al.,
1991), although it is also expressed in other cell types,
including endothelial (Bussolino et al., 1992), myoblasts
(Anastasi et al., 1997), hematopoietic (Nishino et al.,
1995) and neuronal cells (Ebens et al., 1996). HGF
binding triggers receptor activation through dimeriza-
tion and auto/trans-phosphorylation of tyrosine resi-
dues. Two tyrosine residues within the catalytic loop
(Y
1234,Y
1235) are ﬁrst to be phosphorylated, leading to
full kinase activation (Longati et al., 1994). Subse-
quently, two other tyrosine residues (Y
1349,Y
1356) in the
carboxyl-terminal tail are phosphorylated. These are
embedded in a multifunctional consensus sequence
(Ponzetto et al., 1994), acting as a docking site for
different SH2-containing transducers and adaptors
involved in several pathways, including the GRB2–
SOS–RAS–RAF–MEK–ERK (extracellular signal-
regulated protein kinase) pathway, the phosphoinositide
3-kinase–AKT cascade, SRC, STAT3, SHC, PLC-g, cbl,
Gab1 and Rho-like GTPases such as RAC1 (Birchmeier
et al., 2003; Lock et al., 2003).
Different strategies to target Met have the aim of
inhibiting tumor growth and metastatic dissemination
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www.nature.com/onc(Comoglio et al., 2008). Met can be blocked by small-
molecule inhibitors, early examples for which are K252a
(Morotti et al., 2002), SU11274 (Berthou et al., 2004)
and PHA-665752 (Christensen et al., 2003), all of which
compete for ATP binding to block Met catalytic
activity. Several of these molecules (PF-2341066,
XL880, ARQ197, MK2461, MP470, SGX523 and
JNJ38877605) are in phase I/II clinical trials (Zou
et al., 2007; Comoglio et al., 2008). Owing to the way in
which they were selected and the inhibitory mechanism
with which they operate, none of these drugs shows
absolute speciﬁcity for Met, but also target other
kinases, mostly receptor tyrosine kinases (Comoglio
et al., 2008). Higher levels of speciﬁcity in Met inhibition
can be obtained using biological molecules, either
natural or designed expressly on the basis of the
structure of HGF or Met. They act as antagonists that
interfere in the ligand/receptor interaction, which
normally leads to receptor dimerization and subsequent
activation. HGF can be antagonized by its shorter
forms: NK2—a natural fragment of HGF, or NK4—a
truncated form of HGF, or by its uncleavable form, all
of which bind the receptor but cannot fully activate it
(Chan et al., 1991; Matsumoto and Nakamura, 2003;
Mazzone et al., 2004). Similarly, anti-HGF-neutralizing
antibodies act by subtracting functional HGF in the
microenvironment (Cao et al., 2001), some of which are
in pre-clinical or phase II clinical trials (Kim et al., 2006;
Jun et al., 2007), whereas decoy Met, a soluble truncated
Met extracellular receptor domain, both sequesters the
ligand and impairs receptor dimerization (Michieli et al.,
2004). The main limit of using HGF inhibitors is that
they only inhibit HGF-dependent receptor activation.
Few antagonist antireceptor monoclonal antibodies are
available; these antibodies tend to have agonistic rather
than antagonistic properties due to their bivalent
structure (Prat et al., 1998). One promising monoclonal
antibody, DN-30, is able to downregulate Met and
inhibit tumor growth in experimental models (Vigna
et al., 2008). Gene silencing based on antisense,
ribozyme and RNA interference techniques have been
used experimentally to silence Met and HGF expression
(Paranjpe et al., 2007; Corso et al., 2008; Chu et al.,
2009).
Finally, peptides interfering with the association
of signal transducers to the Met receptor docking site
could block the propagation of Met signaling. Previous
studies have shown that a peptide derived from the
carboxyl-terminal tail of Met speciﬁcally inhibited
kinase activity and HGF-induced invasive growth
in normal and transformed epithelial cells in vitro
(Bardelli et al., 1999).
On this basis, we investigated whether synthetic Met
peptides could interfere with angiogenesis in vitro and
in vivo. The peptide was delivered into cells by fusion
with the internalization sequences from either the
Antennapedia homeodomain (Antp) or HIV-Tat pre-
viously shown to translocate peptides efﬁciently across
the plasma membrane (Deshayes et al., 2005; Gupta
et al., 2005; Foged and Nielsen, 2008; Morris et al.,
2008; Stewart et al., 2008).
We show that micromolar concentrations of these
peptides speciﬁcally inhibited HGF-induced in vitro
migration, invasion and morphogenesis of endothelial
cells, interfering with downstream signaling by HGF.
Comparison with the inhibitor PHA-665752 showed
that the peptides exerted greater inhibitory effects, yet
no toxicity, whereas PHA-665752 showed substantial
toxicity. In vivo, the peptides impaired HGF-dependent
angiogenesis and signiﬁcantly inhibited the growth of
Kaposi’s sarcoma xenograft, as well as vascularization.
These data suggest a possible pharmacological mechan-
ism to interfere with Met-mediated angiogenesis.
Results
Cell internalization of the Met docking site peptide
The plasma membrane, which limits cell internalization
of most proteins and peptides, can be crossed by cell-
penetrating peptides, such as Tat and Antp, which can
be used to deliver peptides into living cells. We veriﬁed
efﬁcient peptide internalization by incubating 5-(and-6)-
carboxyﬂuorescein (FAM)-conjugated Tat-Met peptide
(10mM) with human umbilical vein endothelial cells
(HUVEC) and monitoring ﬂuorescence with ﬂow
cytoﬂuorimetry. Peptide uptake was time dependent,
with more than 50% of the cells being ﬂuorescent after
as little as 10min and nearly 100% after 30min
(Figure 1). An FAM-conjugated Met peptide lacking
the Tat cell-penetrating peptide motif did not cross the
cell membrane even after extensive incubation, showing
levels of ﬂuorescence similar to those of control-
untreated HUVEC.
Met docking site peptides inhibit HUVEC proliferation
The cell-penetrating Antp-Met and Tat-Met peptides
were tested for their ability to interfere with HGF-
induced proliferation of HUVEC and compared with
PHA-665752. Signiﬁcant inhibition of cell growth in
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetra-
zolium bromide) assays was observed at doses of 10mM
Antp-Met already after 24h of treatment (Figure 2a).
Higher concentrations of the Antp-Met completely
abolished cell proliferation. Tat-Met and Tat s-Met
(containing a shorter Tat peptide), used at 10mM
concentrations, showed a signiﬁcant reduction of cell
proliferation only after 48h (Figures 2b and c). At higher
concentrations (20 and 50mM) they displayed a cytostatic
activity starting from 24h of incubation. Lower concen-
trations of peptides (1mM) did not have any effect even in
longer treatments.
In contrast, we observed a marked inhibitory effect
starting from the 24-h time point when we exposed
endothelial cells to micromolar concentrations (5 and
10mM) of PHA-665752 (Figure 2d). Lower PHA-665752
concentrations did not exert any signiﬁcant reduction in
proliferation with respect to the control.
These data show that the internalized Met peptides
inhibited cell proliferation; the Antp-coupled Met
peptide appears to have a stronger inhibitory activity,
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trations to attain comparable effects.
Met docking site peptides do not exert toxicity or induce
apoptosis in endothelial cells
The possibility that the Met inhibitors used could exert
toxicity or induce endothelial cell apoptosis was
evaluated by cytoﬂuorimetric analysis. After only 2h
of treatment of endothelial cells in the presence of HGF
with 250nM PHA-665752, approximately 60% of the
cells (Figure 3a) were already undergoing apoptosis
(both Annexin V and 7-amino-actinomycin D positive).
In contrast, cells treated with the peptides, even at
highest concentrations, showed a high percentage
(about 95%) of viable endothelial cells and no apoptosis
(Figure 3a). The toxicity of PHA-665752 was observed
even in the presence of serum (fetal bovine serum
(FBS)) with clear dose-dependent effects (Figure 3b).
These data suggest that the growth inhibition exerted by
PHA-665752 may be due to cytotoxicity and apoptosis.
The Met docking site peptide speciﬁcally inhibits
HGF-dependent HUVEC migration and invasion
Endothelial cells must cross basement membranes
to form new blood vessels during angiogenesis;
we investigated whether the peptides could affect
Figure 1 The Tat-Met peptide enters into HUVECs. Tat-Met was conjugated at the N-terminus with FAM. HUVECs (1 10
5) were
incubated for different periods of time with 10mM peptide, washed twice and analyzed by ﬂuorescence-activated cell sorting. Labeled
Met peptide devoid of the cell-penetrating peptide motif and untreated cells (CTRL) were used as controls. In the lower panels,
representative dot plots of peptide internalization percentage are shown.
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the effect of HGF (50ng/ml), the number of migrated
cells in a Boyden chamber assay doubled; a non-
cytotoxic dose of 10mM peptides abrogated this migra-
tion (Figure 4a; *Po0.05). No signiﬁcant differences in
migration-inhibitory activity were found among the
different peptides. We observed equivalent inhibitory
effects with PHA-6657525 only in the presence of
the highest (cytotoxic) concentrations (5 and 10mM)
Figure 2 The Met docking site peptide inhibits HUVEC
proliferation (MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetra-
zolium bromide)assay). HUVECs were plated at low density, and
then starved in low serum. Cell proliferation was evaluated at ﬁxed
times after the addition of HGF (50ng/ml) þ/  Antp-Met (a),
Tat-Met (b), Tat s-Met (c) or PHA-665752 (d) at different
concentrations in 2% FBS-containing medium. The inhibitory
effect of Antp-Met (10mM) was already signiﬁcant after 24h,
whereas the inhibitory effect of Tat-Met or Tat s-Met peptides were
signiﬁcant only after 48h and when 20mM concentrations were
used. PHA-665752 showed a marked reduction in cell numbers
starting from 24h at micromolar concentrations (5 and 10mM),
whereas lower concentrations did not exert a signiﬁcant reduction
of proliferation with respect to the control. Means±s.e.m. are
shown (Po0.05).
Figure 3 Met docking site peptides do not induce toxicity or
apoptosis in endothelial cells. In the apoptosis assay, HUVECs
were plated onto six-well plates and were treated with either the
Antp-Met peptide (10mM), Tat-Met peptide (10mM) or Tat s-Met
peptide (10mM) or with increasing concentrations of PHA-665752
(250 and 500nM, and 1 and 5mM). Vehicle (dimethyl sulfoxide) and
growth medium alone were used as controls, and HGF 50ng/ml
(panel a) or 10% FBS (panel b) were added to the growth medium.
After 2h, cells were recovered, washed and stained with two
markers, Annexin V and 7-amino-actinomycin D, used to detect
viable, dead or cells undergoing apoptosis. After only 2h, 250nM
PHA-665752 induced late apoptosis in about 60% of endothelial
cells in HGF-containing media (a); on the contrary, 10mM peptides
showed an high percentage of viable endothelial cells (about 95%
of the population; a). The toxicity of PHA-665752 was marked
both in the presence of HGF (a) or FBS (b). The experiment was
performed three times and each condition was in triplicate.
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dependent cell migration (Figure 4c), thus showing clear
speciﬁcity.
In an invasion assay performed in Boyden chambers
with ﬁlters pre-coated with a reconstituted basement
membrane (matrigel), treatment with Tat-Met or Tat
s-Met signiﬁcantly reduced the HGF-induced invasion
(Figure 4d). Tat s-Met displayed a higher inhibitory
activity than Tat-Met (*Po0.05), and in both cases
a dose-dependent effect was observed (Figure 4d).
The Met docking site peptide inhibits endothelial
morphogenesis in vitro
Human umbilical vein endothelial cells can organize into
capillary-like structures when cultured on a thick
matrigel layer in the presence of angiogenic factors.
The Met peptides interfered with HGF-induced
HUVEC morphogenesis with the same efﬁcacy shown
in inhibiting cell proliferation (Supplementary data).
Antp-Met was effective at 10mM (Supplementary data),
whereas Tat-Met and Tat s-Met were effective at 20mM.
Antp-Met did not affect FBS-dependent network
formation, showing speciﬁcity of the inhibitory effect
(Supplementary data). PHA-665752 interfered with
HGF-dependent tube formation to a similar extent as
that of the peptides only at cytotoxic micromolar
concentrations (Supplementary data).
The Met docking site peptide inhibits HGF-dependent
downstream signaling
The different biological responses triggered by HGF and
mediated by Met depend on efﬁcient downstream signal
transduction, which in turn depends on receptor
tyrosine phosphorylation. The binding of HGF leads
to the activation of the two major signaling path-
ways, the ERK1/2 and the phosphoinositide 3-kinase
Figure 4 The Met docking site peptide strongly inhibits HGF-dependent HUVEC migration and invasion. In the migration assay,
HUVECs were seeded into the upper compartment of Boyden chambers in the presence or absence of Antp-, Tat- and Tat s-Met
peptides or PHA-665752, whereas chemoattractants (50ng/ml HGF (a) or 10ng/ml VEGF (c)) were placed in the lower compartment.
After 6h incubation, cells in the upper side of the ﬁlter were removed, and cells that migrated to the lower surface were ﬁxed, stained
and counted. Serum-free medium (SFM) was used as negative control. Met mimicking cell-penetrating peptides inhibited HUVEC
migration induced by HGF, but not that induced by VEGF. The inhibitor PHA-665752 showed the same inhibitory effect of peptides
on HGF-dependent migration only at the highest concentrations (5 and 10mM). The invasion assay was performed similarly, except
that the ﬁlter separating the two compartments was pre-coated with matrigel and incubation was for 18h. Tat- and Tat s-Met peptides
inhibited HGF-induced matrigel invasion in dose-dependent manner (d). All experiments were performed in triplicate and repeated
three times. Means±s.e.m. are shown (*Po0.05).
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We tested whether Antp-Met impaired Met receptor phos-
phorylation in the catalytic loop and in the docking site.
Although phosphorylation on tyrosines 1234 1235,
localized in catalytic loop, was not affected, phospho-
rylation on tyrosine 1349, localized in the carboxyl-
terminal docking site, showed a 70% reduction when
Antp-Met was added to cells 2h before stimulation
with 10ng/ml HGF (Figure 5a). Phosphorylation of
ERK1/2, which is mainly involved in transducing
proliferation and motility responses (Prat et al., 1998;
Birchmeier et al., 2003), was also impaired by the Antp-
Met peptide (Figure 5a). Taken together, these data
show that Met-derived peptides inhibit the phospho-
rylation of the tyrosines located in this motif, and block
activation of the downstream signaling, but do not
affect phosphorylation of the tyrosines located in the
activation loop.
The Met docking site peptide inhibits in vivo angiogenesis
We assessed the effect of the Met peptides on in vivo
angiogenesis using a rapid and quantitative matrigel
sponge assay. A cocktail of HGF (50ng/ml) and heparin
(50U/ml) promoted a hemorrhagic vascularization of
the matrigel sponge, which was clearly detectable at 4
days post-implantation (Figure 6a). Addition of the
different Met-derived peptides (10mM) signiﬁcantly
inhibited the HGF-induced angiogenic response, as
detected by visual inspection of the pellets and measured
in a hemoglobin quantiﬁcation assay (***Po0.001)
(Figure 6b). The inhibition was speciﬁc, as shown by the
lack of effect on the angiogenic response of an Antp-
Met peptide whose sequence had been scrambled
(Figure 6b). Hematoxylin- and eosin-stained sections
of pellets showed that the extensive vascularized areas in
mice treated with HGF and heparin were substantially
reduced in mice treated with the Met peptides (10mM)
(Figures 6Ca, b, c).
Immunohistochemistry showed that CD11b/c-posi-
tive cells were readily detected within pellets containing
HGF and heparin, indicating the presence of an
inﬂammatory response; this inﬁltrate was signiﬁcantly
reduced when Met peptides were co-injected in matrigel
(Figures 6Ca0,b 0,c 0).
The Met docking site peptide inhibits the growth and
vascularization of Kaposi’s sarcomas in nude mice
We next examined whether the peptides were able to
effect growth and vascularization of tumors in vivo. KS-
Imm Kaposi’s sarcoma cells were injected in liquid
matrigel with or without Tat s-Met (10mM), followed by
treatment with peptides subcutaneously every second
day until termination of the experiment. Treatment with
the Tat s-Met peptide clearly inhibited tumor growth
(Figure 7a). Hematoxylin–eosin staining of sections of
tumors showed extensive areas of vascularization in
control tumors, whereas extensive necrotic areas and
strongly reduced vascularization were found in tumors
of animals receiving peptides (Figures 7Ba, b). Immuno-
histochemical staining indicated that in peptide-treated
tumors CD11b/c-positive inﬂammatory cells were sig-
niﬁcantly reduced (Figures 7Ba0,b 0). To conﬁrm the
reduction of vascularization in tumors treated with
peptide, we performed an immunoﬂuorescence analysis
for the endothelial marker von Willebrand (Figures
7Cb, b0) and we observed a higher number of von
Willebrand-positive cells (Figure 7Cb) in control tumors
than in tumors treated with Tat s-Met (Figure 7Cb0). We
observed colocalization of the Met receptor and the von
Willibrand endothelial marker in the tumors
(Figures 7Cc, c0), suggesting that murine tumor endo-
thelial cells express Met. This was consistent with the
presence of Met (Figure 5b) in the 1G11 murine lung
microvascular endothelial cell line (Dong et al., 1997).
In another set of experiments, Antp-Met, or a
scrambled peptide (both at 10mM), was injected in the
peri-tumor area every second day after the tumor was
established. Again, the peptide signiﬁcantly inhibited
tumor growth, whereras the scrambled peptide had no
effect on tumor growth (Figure 7D). The central
necrotic areas (Figures 7Ea, b) and the strong inﬂam-
matory inﬁltrate (Figures 7Ea0,b 0) again were strongly
reduced in the presence of the Met peptide as compared
with controls receiving either vehicle alone or scrambled
peptide. These data indicate that the Met peptides, while
not toxic for healthy endothelial cells, strongly and
speciﬁcally inhibited tumor angiogenesis, inﬂammation
and growth.
Figure 5 The Met docking site peptide inhibits the HGF-
dependent downstream signaling. Quiescent HUVECs were pre-
treated or not for 2h with Antp-Met before stimulation with 10ng/
ml HGF for 15min, and then lysed and processed for Western blot
analysis. Blots were probed with anti-phospho Met (tyrosine 1349),
anti-phospho Met (tyrosines 1234–1235), anti-phospho ERK1/2,
anti-Met and anti-a-tubulin. Antp-Met inhibited the phosphoryla-
tion of tyrosine 1349, but not of tyrosines 1234–1235. Besides, the
phosphorylation of ERK1/2 was impaired by Antp-Met (a).
(b) Human and murine endothelial cell lines, HUVEC and 1G11,
respectively, express Met receptor protein.
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Angiogenesis is associated with several pathologies,
including chronic inﬂammation and arthritis, athero-
sclerosis, macular degeneration and cancer (Carmeliet
and Jain, 2000); therapeutic strategies have envisioned
angiogenesis as a promising target (Folkman, 1985;
Carmeliet and Jain, 2000; Ferrara, 2004; Goh et al.,
2007). HGF and its receptor Met are able to stimulate
endothelial cell migration, proliferation and organiza-
tion into capillary-like tubes and angiogenesis (Busso-
lino et al., 1992; Grant et al., 1993; Silvagno et al., 1995).
HGF can induce pro-angiogenic cytokine expression,
directly activating angiogenic pathways (Dong et al.,
2001; Sengupta et al., 2003) or downregulating the
expression of angiogenic inhibitors (Zhang et al., 2003)
and promoting lymphangiogenesis (Cao et al., 2006).
The HGF/Met axis has been proposed as a target for
antiangiogenic therapy (You and McDonald, 2008).
Structural and functional integrity of endothelial cells
is a fundamental factor for vessel homeostasis and
function. Alterations in the endothelium are associated
with increased risk for several diseases, including
cardiovascular diseases and adverse events. Agents
affecting endothelial integrity, inducing apoptosis or
direct toxicity, are likely to induce vascular dysfunction.
Several small-molecule drugs targeting Met and other
kinases show toxicity; biological molecules could be
used to obtain higher levels of speciﬁcity and lower
toxicity in Met inhibition.
Here we describe the antiangiogenic properties of
synthetic cell-permeable peptides containing the carboxyl-
terminal tail of Met in the absence of cytotoxicity or
apoptosis induction. These peptides inhibit HGF-induced
proliferation, migration, invasiveness and capillary-like
network formation in endothelial cells in vitro. Comparison
of our peptides with the ATP-competitive inhibitor PHA-
665752 showed that similar inhibitory effects were obtained
only at high concentrations of PHA-665752 that were
associated with apoptosis and toxicity. The ability of these
peptides to interfere with pathological responses with no
cytotoxic effects would be of clinical relevance to minimize
the additive toxicity phenomena due to the administration
of multiple inhibitor drugs.
The Met docking site peptides were active in vivo,
blocking HGF-induced angiogenesis and restraining
growth and vascularization of xenografted tumors; this
is the ﬁrst report of the in vivo inhibiting activity of
a Met-speciﬁc cell-penetrating peptide. Homozygous
genetic deletion of either Met or HGF is lethal in utero
due to defects in placental development (Bladt et al., 1995;
Schmidt et al., 1995; Uehara et al., 1995). However, the
Met /  mice did not show an endothelial phenotype
Figure 6 The Met docking site peptide inhibits in vivo angio-
genesis. A cocktail of HGF (50ng/ml) and heparin (50U/ml)
promoted a hemorrhagic vascularization of the matrigel sponge
clearly detectable at 4 days post-implantation. HGF-induced
vascularization of the subcutaneously injected matrigel implants
was signiﬁcantly inhibited by the addition of micromolar concen-
tration of Met peptides, as detectable at visual inspection (A) and
quantiﬁed by measuring hemoglobin (Hb) content of the pellets (B)
(***Po0.001). Representative histological specimens that were
stained with hematoxylin and eosin show extensive necrotic areas
(C (a, b and c)). CD11b/c immunohistochemistry on adjacent
sections show abrogation/impairment of cellular inﬁltrates in the
pellets treated with the peptides (C (a0,b 0 and c0)) ( 400
magniﬁcation).
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endothelium in HGF /  embryos was not altered
(Uehara et al., 1995). These data suggest that the Met/
HGF axis may have a major role in pathological but not
in physiological angiogenesis, as proposed for other
angiogenic factors such as PlGF (Fischer et al., 2008).
This would be consistent with the role of Met in
endothelial cells (Figure 6b), the co-expression with the
endothelial marker in vivo (Figure 7b) and the lack of
toxicity in vitro and in vivo.
Biochemically, the peptides strongly impaired HGF-
dependent activation of the Ras-MAPK ERK1/2
transduction pathway (Ponzetto et al., 1994; Birchmeier
et al., 2003), consistent with previous in vitro studies in
epithelial cells (Bardelli et al., 1999). The Met-speciﬁc
peptides were delivered into cells by fusion with the
internalization sequences from the Antp homeodomain 3
or the HIV-Tat basic domain, which proved to act
efﬁciently as transporters across membranes (Deshayes
et al., 2005; Gupta et al., 2005; Foged and Nielsen, 2008;
Morris et al., 2008; Stewart et al., 2008). A similar
peptide fused to the Tat internalizing sequence enhanced
in vitro chemosensitivity of glioma cells to a cis-platinum
derivative (Lou et al., 2009). The three peptides
containing the Met docking site coupled to different
internalizing sequences showed only small differences in
their inhibitory efﬁciency in vitro and in vivo. The three
peptides displayed clear speciﬁcity for Met receptor;
they did not impair VEGF- or FBS-induced effects on
endothelial cells in vitro and a scrambled peptide was
ineffective in vivo.
The Met-speciﬁc peptide inhibited the phosphoryla-
tion of Y
1349, which binds the p85 regulatory subunit of
phosphoinositide 3-kinase (Graziani et al., 1991; Pon-
zetto et al., 1994; Bardelli et al., 1999; Lou et al., 2009),
mainly involved in transducing HGF-dependent moto-
genic and antiapoptotic responses (Ponzetto et al., 1993;
Khwaja et al., 1998; Giordano et al., 2000; Deregibus
et al., 2003). Phosphorylation of the MAPK ERK1/2,
whose activation is required for the proliferative and
invasive responses (Ponzetto et al., 1994; Prat et al.,
1998; Birchmeier et al., 2003; Bardelli et al., 2005), was
impaired. Although strongly interfering with the activa-
tion of the tyrosines located in the docking site, the
peptide had no effect on phosphorylation of Y
1234,Y
1235,
localized in the activation loop, as it appears to compete
with substrate access to the catalytic pocket (Bardelli
et al., 1999).
Current clinical approaches to targeting angiogenesis
have focused on blocking VEGF signaling by either
anti-VEGF antibodies or multitargeted receptor tyro-
sine kinase inhibitors (Folkman, 1985; Carmeliet and
Jain, 2000; Ferrara, 2004; Goh et al., 2007; Loges et al.,
2009). Current clinical experience has revealed that
VEGF-targeted therapy prolongs overall survival of
cancer patients by only months, and experimental
models have recently shown that anti-VEGF treatment
inhibits primary tumor growth, but may promote
invasiveness and metastasis (Pennacchietti et al., 2003;
Ebos et al., 2009; Paez-Ribes et al., 2009). The fact that
Met is both a pro-angiogenic factor and an oncogene
suggested that it may be an optimal target for anticancer
treatment, simultaneously inhibiting angiogenesis and
oncogenesis (Michieli et al., 2004) and potentially
complementing VEGF targeted antiangiogenic therapy.
Our observations provide the novel result that Met-
speciﬁc peptides mimicking the tail multifunctional
docking site can block angiogenesis and consequent
cancer growth and related metastatic dissemination.
Materials and methods
Reagents
Murine recombinant VEGF-A, human recombinant VEGF-
A165, murine recombinant tumor necrosis factor-a and human
recombinant HGF in its biologically active form (Gherardi
et al., 2006) were purchased from Peprotech (Offenbach,
Germany); heparin was obtained from Sigma (Sigma-Aldrich
Chemie, Taufkirchen, Germany). Matrigel was prepared from
the Engelbreth–Holm–Swarm sarcoma as described previously
(Kleinman et al., 1986).
Cell-permeable peptides containing the Met docking site
sequence (ref. seq: NP_000236), or a control scrambled
sequence, fused to the internalization sequences of either the
homeodomain 3 of the Antennapedia protein (ref. seq:
NP_996167) or the Tat transactivator domain (ref. seq:
NP_057853) at their N-terminus were synthesized and puriﬁed
by Primm (Milan, Italy). Two Tat sequences of different
lengths were used. Peptides conjugated to FAM at their
N-terminus were used to evaluate internalization. Peptide
sequences are reported in Table 1.
Cell cultures
Human umbilical vein endothelial cells were purchased from
Promo Cell (Heidelberg, Germany) and grown on 1% gelatin-
coated tissue culture plates in M199 endothelial growth
medium (Sigma, St Louis, MO, USA), supplemented with
10% heat-inactivated FBS, 1% L-glutamine, ﬁbroblast growth
factors (1mg acid-ﬁbroblast growth factor plus 1mg basic-
ﬁbroblast growth factor /100ml), epidermal growth factor
(1mg/100ml), heparin (10mg/100ml) and hydrocortisone
(0.1mg/100ml). Cells were used between the second and
eighth passage in vitro. The murine lung endothelial cell line
(1G11) was the kind gift from Annunciata Vecchi (Istituto
Clinico Humanitas, IRCCS and University of Milan, Milan,
Italy).
Cytoﬂuorimetric analysis
Human umbilical vein endothelial cells (6 10
5) were incu-
bated with 10mM concentrations of FAM-labeled peptides for
different periods of time (10, 30, 60 and 120min). Cells were
then recovered, washed twice with phosphate-buffered saline
(PBS), ﬁxed in 4% paraformaldehyde and analyzed by ﬂow
ﬂuorocytometry in a FACSCanto (BD Biosciences, San Jose,
CA, USA).
To compare the effect of our peptides with that of the Met-
speciﬁc inhibitor PHA-665752 (the kind gift of Professor Livio
Trusolino, Univ. Torino), 1 10
5 HUVECs were plated onto
six-well plates and allowed to adhere overnight. The next day,
the cells were treated in the growth medium (in the presence of
HGF 50ng/ml or 10% FBS) with the Antp-Met peptide
(10mM), Tat-Met peptide (10mM) or Tat s-Met peptide (10mM)
or with increasing concentrations of PHA-665752 (250 and
500nM, and 1 and 5mM). Dimethyl sulfoxide and growth
medium alone (in the presence of HGF 50ng/ml or 10% FBS)
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with PBS and transferred to test tubes. Cells were pelleted and
resuspended in Annexin V-binding buffer (0.01 M HEPES
(4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) (pH 7.4);
0.14 M NaCl; 2.5mM CaCl2). Fluorescein isothiocyanate
Annexin V and 7-amino-actinomycin D (BD Biosciences)
were added to each test tube and incubated for 15min at room
temperature in the dark. Cells were then washed in PBS,
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buffer. Samples were acquired by ﬂow ﬂuorocytometry using a
FACSCanto (BD Biosciences) and analyzed using FACSDiva
Software 6.1.2. The experiment was performed three times and
each condition was a triplicate.
In vitro cell viability
Human umbilical vein endothelial cell viability was evaluated
in the MTT assay. Cells (1000/well) were seeded into 96-
multiwell plates in complete medium and, after complete
adhesion, the medium was replaced with 2% FBS fresh
medium with or without 50ng/ml HGF and/or different pep-
tides at different concentrations (1–50mM) or with or without
PHA-665752 at increasing concentrations (250nM–10mM).
After different periods of incubation (24, 48, 72 and 96h),
plates were processed and absorbance read at 570nm.
Migration, invasion and morphogenesis assays
These assays were performed in modiﬁed Boyden chambers, as
described previously (Albini et al., 1987; Albini and Benelli,
2007). HUVECs (5 10
4) were washed with PBS, resuspended
in serum-free medium and placed in the upper compartment.
Chemoattractants (50ng/ml HGF or 10ng/ml VEGF) in
serum-free M199 medium were added in the lower compart-
ment and the different peptides or PHA-665752 at different
concentrations added. Pore-size polycarbonate ﬁlters (12mM)
were pre-coated with collagen (50mg/ml) or matrigel (1mg/ml).
After 6h (migration) or overnight (invasion) incubation, the
ﬁlters were recovered, cells on the upper surface mechanically
removed and cells migrated to or invaded the lower ﬁlter
surface ﬁxed with absolute ethanol and stained with toluidine
blue. Cells were counted in a double-blind manner in eight
consecutive ﬁelds each with a light microscope. All experi-
ments were performed three times in triplicate. The in vitro
morphogenesis assay was performed as described by Grant
et al. (1989) in the presence of 50ng/ml HGF or 10% FBS, and
with the peptides or PHA-665752 in increasing concentrations.
After 6h incubation on matrigel, the dimensional organization
of the cells was examined under an inverted microscope (Zeiss,
Oberkochen, Germany), equipped with CCD optics and a
digital analysis system.
Western blotting
Human umbilical vein endothelial cells, pre-incubated in
serum-free medium for 24h, were pre-treated for 2h with
10mM Antp-Met peptide before stimulation with 10ng/ml
HGF for 15min (Prat et al., 1998). Lysates were prepared
using Cell Lysis Buffer (Cell Signaling Technology, Beverly,
MA, USA) and protein concentrations evaluated by the DC
Protein Assay (Bio-Rad, Hercules, CA, USA). Proteins were
separated on 8% SDS–polyacrylamide gel electrophoresis
under reducing conditions and transferred onto polyvinylidene
ﬂuoride membranes (Amersham, Biosciences, Otelﬁngen, CH,
USA), which were then incubated with the antibodies directed
against the following human antigens: phospho-ERK1/2,
tubulin, phospho-Met (tyrosine 1349), phospho-Met (tyrosines
1234–1235) (Cell Signaling Technology) and Met (Santa Cruz
Biotechnology Inc, Santa Cruz, CA, USA) diluted in 5%
bovine serum albumin–Tris-buffered saline–0.1% Tween.
Horseradish-peroxidase-conjugated secondary antibodies
against rabbit or anti-mouse immunoglobulin (Cell Signaling
Technology; 1:5000) were then used and reactions were
visualized with the enhanced chemiluminescence kit (ECL)
from Amersham Biosciences (Pittsburg, PA, USA). Lysates,
HUVEC and 1G11 cells, were incubated with antibodies
directed against human Met and mouse Met (both provided by
Santa Cruz Biotechnology Inc), respectively.
In vivo matrigel sponge assay
The assay was performed as described (Albini et al., 1994).
HGF (50ng/ml in the presence of heparin 50U/ml), with or
without peptides, was added to unpolymerized liquid matrigel
and slowly injected subcutaneously into the ﬂanks of 6- to
8-week-old C57/BL6 male mice (Charles River Laboratories,
Calco (Lecco), Italy) in groups of 4–8 mice for each treatment.
Four days after injection, the animals were killed and the
pellets were removed, weighed, and either formalin-ﬁxed and
parafﬁn-embedded for histological examination, or minced
and diluted in water for hemoglobin content measurement
with a Drabkin reagent kit (Sigma). The ﬁnal hemoglobin
Table 1 Peptide sequences
Antp-Met RQIKIWFQNRRMKWKK IGEHYVHVNATYVNV
KCVA
Tat-Met GRKKRRQRRRPP IGEHYVHVNATYVNVKCVA
Tat s-Met RKKRRQRRR IGEHYVHVNATYVNVKCVA
Antp-
scrambled
RQIKIWFQNRRMKWKK IVAVNCGV-
HYEHTNVKVYA
Met IGEHYVHVNATYVNVKCVA
Cell-permeable peptides derived from the Met receptor docking site
fused to internalization sequences from the Antennapedia and Tat
proteins. Met sequence alone was used as control of cell internalization.
Figure 7 The Met docking site peptide impairs the growth and vascularization of established Kaposi’s sarcomas in nude mice. Mice
with xenografted Kaposi’s sarcoma tumors (either established (D, E) or not (A, B)) were injected peri-tumorally with equimolar
concentrations of either Antp-Met, Tat s-Met or Antp-scrambled (150ml ﬁnal volume of a 10mM solution) or vehicle alone (control)
every second day, as indicated. (A) Tumor growth analysis showed a signiﬁcant inhibition of tumor growth by Tat s-Met. The inset
shows a quantitative analysis of the areas necrosis (as a percentage) in control and Tat s-Met-treated tumors (mean±s.e.; *Po0.001).
(B) Hematoxylin and eosin staining of the Kaposi’s sarcoma xenografts grown in mice treated with Tat s-Met (b) showed extensive
necrotic areas, when compared with tumors from control mice receiving only vehicle (a). Immunostaining of adjacent sections with
CD11b/c, a marker of inﬂammatory inﬁltrates, showed that Tat s-Met treatment strongly inhibited the inﬂammation associated with
the tumor (b0), relative to treatment with vehicle alone (control) (a0). (C) Immunoﬂuorescence staining of Kaposi’s sarcoma xenograft
sections for the endothelial marker von Willibrand (b and b0) and Met receptor (c and c0). The number of positive von Willibrand cells
in control tumors (b) was much higher than that in xenografts treated with Tat-s (b0). The effect of the peptide on vascularization was
Met-related, as showed by the colocalization of the Met receptor with the von Willibrand endothelial cell marker in the tumors (c and c0).
(D) Antp-Met peptide was also able to signiﬁcantly inhibit tumor growth in vivo. In contrast, a scrambled control peptide had no effect
on tumor growth, showing the role of speciﬁc Met inhibition. The inset shows a quantitative analysis of the areas necrosis (as a
percentage) in control and Antp-Met-treated tumors (mean±s.e.; ***Po0.001). (E) Hematoxylin and eosin staining of the Kaposi’s
sarcoma xenografts grown in mice treated with Antp-Met (b) showed extensive necrotic areas, as compared with tumors from control
mice receiving only vehicle (a). CD11b/c immunostaining of adjacent sections also showed a strong Antp-Met inhibition of tumor-
associated inﬂammation (b0) as compared with controls (a0)( 400 magniﬁcation).
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curve, after spectrophotometric analysis at 540nm.
In vivo xenograft tumor growth
Xenografted tumors were obtained by subcutaneous injection
of 5 10
6 human KS-Imm cells/mouse, and mixed with liquid
matrigel into the ﬂanks of seven-week-old male nude nu/nu
(CD-1) BR mice (Charles River Laboratories) as described
previously (Albini et al., 1997, 2001). Tat s-Met peptide was
injected with cells (300ml ﬁnal volume of 10mM peptide
corresponding to 34mg/ml) and then every second day by
peri-tumor injection, whereas control animals received vehicle
alone. In another experiment, the Antp-Met peptide (300ml
ﬁnal volume of 10mM peptide corresponding to 43mg/ml)
was injected after the tumors had become established.
Animals were weighed and tumor growth monitored at regular
intervals by measuring the two tumor diameters with a caliper.
After the animal was killed, tumors were removed, weighed
and processed for histological examination. All procedures
were performed in adherence with the ECC Directive for
Care and Italian Laws on animal experimentation (Law by
Decree 116/92).
Histological analysis
Sections of 3mM thickness were stained with hematoxylin–
eosin for histological examination. For immunohistochemis-
try, slides were deparafﬁnized in xylene, rehydrated and
antigens retrieved in EDTA (pH 8); thereafter, the sections
were treated with 3% of hydrogen peroxide, incubated with
rabbit polyclonal CD11b/c antibody (1:600) (ABR, Golden,
CO, USA) and peroxidase-coupled anti-rabbit immunoglobu-
lin secondary antibodies, followed by reaction with 3,30-
diaminobenzidine (Dako REAL EnVision system, Peroxidase/
diaminobenzidineþ, Dako, Glostrup, Denmark) and ﬁnally
counterstained with Mayer’s hematoxylin (Sigma).
For immunoﬂuorescence microscopy, primary antibodies
against von-Willibrand factor (rabbit anti-mouse, 1:100)
(Millipore, Temecula, CA, USA) and Met (mouse anti-mouse,
1:100) (Santa Cruz Biotechnology Inc) were diluted in back-
ground reducing diluent (Dako) and applied for 1h at room
temperature, after the incubation with blocking serum (3%
goat serum). Fluorescent secondary antibodies Alexa Fluor
goat anti-rabbit 488 (1:50) (Invitrogen, Eugene, OR, USA) and
goat anti-mouse 555 (1:30) (Invitrogen) were diluted in PBS
buffer and applied for 1h at room temperature. Nuclei were
labeled with Vectashield mounting medium (Vector Labora-
tories, Burlingame, CA, USA).
Statistical analyses
Statistical analyses were performed using two-tailed t-tests for
comparison of two data sets, one-way analysis of variance for
multiple data sets and two-way analysis of variance for growth
curves, using the Graph Pad Prism statistics and graphing
program.
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